# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Following the closing, NanoString's business operations will no longer be the subject of a chapter 11 proceeding and will b...
Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:BRKR) with a Sell and raises the price target from $66 to $74.
Bruker Corporation (NASDAQ:BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces th...
Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific researc...
UBS analyst John Sourbeer maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price target from $94 to $102.
As reported in an 8-K SEC filing on December 26, 2023, Bruker had previously entered into a put option agreement with the selle...
https://www.sec.gov/Archives/edgar/data/1649339/000090514824000653/xslForm13F_X02/informationtable.xml